EFFICIENCY OF SILDANEFIL MONOTHERAPY IN BENIGN PROSTATIC HYPERPLASIA
| Autor: | Sasa Vojinov, Vuk Sekulic, Dragan Grbic, Dimitrije Jeremic, Ivan Levakov, Senjin Djozic |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Sildenafil Urology Prostatic Hyperplasia Sildenafil Citrate law.invention chemistry.chemical_compound Randomized controlled trial law Lower urinary tract symptoms medicine Humans Prospective Studies business.industry General Medicine Hyperplasia Middle Aged Phosphodiesterase 5 Inhibitors medicine.disease Phosphodiesterase Type 5 Inhibitors Erectile dysfunction Treatment Outcome chemistry Concomitant International Prostate Symptom Score business |
| Zdroj: | Medicinski pregled. 69(11-12) |
| ISSN: | 0025-8105 |
| Popis: | Introduction. High incidences of benign prostatic hyperplasia and lower urinary tract symptoms have a high socioeconomic importance. There are several published studies which have proved the efficiency of phosphodiesterase type 5 inhibitors in treatment of benign prostatic hyperplasia and lower urinary tract symptoms. However, more studies are needed to make this therapy the standard option for treating benign prostatic hyperplasia and lower urinary tract symptoms. This study was aimed at exploring changes in International Prostate Symptom Score, post voiding residuum and maximal urine flow in benign prostatic hyperplasia and lower urinary tract symptoms patients treated by sildenafil for benign prostatic hyperplasia and lower urinary tract symptoms. Material and Methods. This study, which was conducted as a prospective, controlled, opened, randomized study, included 30 patients with benign prostatic hyperplasia and lower urinary tract symptoms. Research was conducted at the Department of Urology, Clinical Center of Vojvodina (November 2011 till November 2012). The inclusion criteria were as following: >45 years of age, International Prostate Symptom Score >3, prostatic specific antigen |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|